-
#newbornscreening is the missing piece of the#RareDisease#EU policies. Together we will ensure this changes! Thank you@MPizarroPorto@MetzTilly@spietikainen and all other Members of the@EUParl_EN for your support!@ipopi@ESIDsociety#ISNS#primaryimmunodeficiency#SCIDhttps://twitter.com/ipopi_info/status/1224716791609536512 …
-
A New Lease On Life! : Good early results with
#genetherapy for rare#immunedeficiency#XLinkedChronicGranulomatous#primaryimmunodeficiency#TuesdayThoughts#TuesdayMotivationhttps://twitter.com/BostonChildrens/status/1223320041086767104 … -
The rapid pace of newly-IDd
#PrimaryImmunodeficiency mutations continues *And a reminder that these oft-times deadly immunological disorders primarily affect children https://link.springer.com/article/10.1007%2Fs10875-020-00760-3 …#rstats#iot#technology#snrtg#bigdata#scicomm#genomics#immunology#RareDiseasepic.twitter.com/EZKZaZDAWj
Prikaži ovu nit -
Learning the basic in
#XLinkedCGD diagnosis.. DHR assay is an effective and fast way of diagnosing CGD.#Primaryimmunodeficiency#paediatric https://mpaeds.my/journals/index.php/MJPCH/article/view/88/42 …pic.twitter.com/54Qd8M4dk6
-
@Vision4Health state of health in the EU highlights#vaccine hesitancy as major public health threat across the#EU. Let's counter disinformation! Facts first:#VaccinesSaveLives protecting you, your children & others, especially the most vulnerable!#primaryimmunodeficiency pic.twitter.com/cbqlsEDPCm
-
A big shout out of support to the
#primaryimmunodeficiency community who are preparing for the 10th#WorldPIWeek in April!https://twitter.com/WorldPIWeek/status/1222825278189309953 …
-
This Blog post from I.G. Living speaks about the importance of self-advocacy. This is particularly important for patients living with long-term
#ChronicIllness such as#PrimaryImmunodeficiency. "I am the Captain of My Own Healthcare Ship." http://ow.ly/E9co50y6xLq -
Thank you to everyone that follow us and helping us reach 1000 followers!
#primaryimmunodeficiency#livingwithpi#pidcare#piawareness#ThankYoupic.twitter.com/dNRaJ4dT0v
-
Autoimmunity & Primary Immunodeficiency disorders -Two highly unlikely disease "partnerships" increasingly being co-identified via genomic science https://bit.ly/3b4fT2d
#serverless#meded#scicomm#bigdata#iot#snrtg#autoimmune#PrimaryImmunodeficiency#genomics#RareDiseasepic.twitter.com/UuZdOEijmM
Prikaži ovu nit -
Congratulations to
@ireneliang_ for being our winner for our Flu Shot Contest! Thank you to everyone that helped us raise awareness about the flu#primaryimmunodeficiency#flushot#contest#livingwithpi#fluawareness#piawareness#pidcarepic.twitter.com/05egsRg5aw
-
Flu Shot Awareness - Talk to your health care provide to determine if the flu shot is the right choice for you and your family
#flushotawareness#flushot#flu#primaryimmunodeficiency#pidcare#piawareness#livingwithpipic.twitter.com/1oL0Ru01y1
-
Today we feature Goodpasture syndrome, which is a rare autoimmune disorder characterized by inflammation of the filtering structures of the kidneys & excessive bleeding into the lungs. Credit NORD
#primaryimmunodeficiency#health#raredisease#piawareness#PIDcare#livingwithPIpic.twitter.com/KrtB2tewYF
-
Scientists suspected a never-before-described
#PrimaryImmunodeficiency disorder -DNA sequencing proved them correct... _News: https://www.rockefeller.edu/news/27419-unusual-patient-case-cmv-rare-immune-deficiency/ …#serverless#rstats#itrtg#technology#iot#bigData#scicomm _Journal: https://www.nejm.org/doi/full/10.1056/NEJMoa1910640 …#genomics#immunology#RareDiseasepic.twitter.com/lHySABqzDl
Prikaži ovu nit -
2020 marks the 10th anniversary of
#WorldPIWeek! We are delighted to announce that this year's campaign focuses on celebrations: celebrating life, achievements & what keeps the#primaryimmunodeficiency community going. Join us for this special milestone! https://bit.ly/2uNUPw0 pic.twitter.com/FimOUTYjD7
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.









